Background-Atrial fibrillation recurrence after pulmonary vein (PV) isolation is associated with PV to left atrium reconduction. We prospectively studied the use of 2 procedural techniques designed to facilitate identification of residual gaps within the index ablation line. Methods and Results-After wide circumferential PV isolation, 40 patients received additional ablation targeted at locations of left atrial capture during high-output pacing (pace-capture group), while 40 patients underwent adenosine testing with targeted ablation at sites of dormant conduction (adenosine group). Patients were followed up at 3, 6, and 12 months. After PV isolation, high-output pace-capture was documented in 39 PVs (25%; 50% of patients) in the pace-capture group. Dormant conduction was unmasked in 34 PVs (22%; 53% of patients) in the adenosine group. A subset of 25 patients in the pacecapture group underwent adenosine testing without targeted ablation of dormant conduction. In these patients, only 10 out of 86 PVs (11.6%; 24% of patients) demonstrated dormant conduction after the elimination of local pace-capture. At a followup of 329±124 days, the single procedure off antiarrhythmic drug freedom from recurrent atrial fibrillation was 67.5% in the adenosine group and 65.0% in the pace-capture group (P=0.814). Procedure duration and fluoroscopy time were significantly longer in the pace-capture group (P=0.002 and P<0.001), whereas radiofrequency ablation time was comparable (P=0.192). Conclusions-The use of high-output pacing post-PV isolation results in a significant reduction in the incidence of dormant conduction with a comparable long-term freedom from recurrent atrial fibrillation (versus adenosine-guided ablation). The use of these approaches requires evaluation in a long-term prospective randomized study.
A trial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and is associated with reductions in quality of life, functional status, cardiac performance, and overall survival. 1 Radiofrequency catheter ablation centered on electric isolation of triggering foci within the pulmonary veins (PVs) through circumferential lesions around PV ostia (PV isolation [PVI] ) and elimination of the arrhythmic substrate, has been shown to be a highly effective option for patients with both paroxysmal and persistent AF. 2 Unfortunately, despite an initial procedural success, ≤20% to 40% of patients will require a second intervention attributable to arrhythmia recurrence, which is most often attributable to recovery of conduction between PVs and the left atrium (LA).
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Two procedural techniques aimed at identifying regions of incomplete ablation and residual gaps within the ablation lines have been postulated to reduce PV reconnection. One such technique is the use of intravenous adenosine to differentiate permanent PV-atrial block from dormant conduction (ie, viable but latently nonconducting tissue). Thereafter, further ablation targeted to sites of dormant conduction can be performed with the goal of eliminating sites of acute, adenosine-provoked reconnection. [9] [10] [11] [12] [13] An alternative strategy is the pace-captureguided approach, whereby, after completion of PVI, the antral ablation line encircling the ipsilateral PVs is mapped while December 2013 pacing from the ablation catheters distal electrode pair. 14, 15 Where local LA capture is identified, additional ablation can be performed with the goal of closure of the residual gaps. The purpose of this study is to validate the use of a pace-captureguided approach, in comparison with adenosine administration for the identification of residual or dormant PV conduction.
Methods
Study Population
Eighty consecutive patients with highly symptomatic paroxysmal AF refractory to antiarrhythmic drugs referred for catheter ablation between August 2010 and May 2011 were prospectively enrolled in this pragmatic parallel cohort study. All patients had structurally normal hearts as assessed by clinical evaluation and cardiac imaging (echocardiography, computed tomography, and MRI). The study was approved by the local institutional review committees. Written informed consent was obtained from each participant.
Pulmonary Isolation Procedure
Effective anticoagulation with oral vitamin K antagonists (international normalized ratio, 2-3) or dabigatran for ≥1 month and the exclusion of a LA thrombus by a recent transesophageal echocardiogram were realized before ablation. Antiarrhythmic drugs were discontinued before the procedure, allowing a washout period of 5 half-lives (except for amiodarone).
All patients underwent catheter ablation with an irrigated-tip radiofrequency ablation catheter using standard techniques. Specifically, via central venous access, a multipolar catheter was placed in the coronary sinus to guide electroanatomic mapping, and facilitate left atrial pacing. LA access was obtained via dual trans-septal puncture or patent foramen ovale. After trans-septal access, intravenous heparin was administered as a bolus with continuous infusion to maintain an activated clotting time >300 seconds. Through 1 transseptal access, a variable decapolar circular mapping catheter (Lasso, Biosense-Webster, Diamond Bar, CA) was advanced into the LA for mapping and confirmation of PVI. Via the second trans-septal access, an irrigated 3.5 mm tip mapping and ablation catheter (Thermocool, Biosense Webster; or SaphireBlu, St Jude Medical, Minneapolis, MN) was advanced into the LA via a long sheath. All procedures were guided by a 3-dimensional electroanatomical mapping system (CARTO, Biosense-Webster, or Ensite NavX, St Jude Medical). Before ablation, the circular mapping catheter was placed sequentially within each of the 4 PV antra to record baseline electric activity (PV potentials). The ostia and antra of the PVs were defined through a combination of examination of the 3-dimensional electroanatomical shell, pulmonary venography, tactile catheter feedback, catheter impedance changes, signal mapping as the catheter was withdrawn from inside the vein, and when available, intracardiac echocardiography.
Targeting ipsilateral PVs in pairs radiofrequency catheter ablation lesions were placed a minimum of 1 m outside of the PV ostia using a standard wide circumferential antral isolation approach. Ablation was allowed within 1 cm of the ostium of the left superior PV because of the narrow ridge of tissue between its anterior aspect and the left atrial appendage. Radiofrequency energy was delivered at a target temperature of 50°C, at a power of 30 to 35 W, and at an irrigation flow rate of 17 to 30 mL/min. On the posterior wall, the RF power was reduced to 25 W with a flow of 17 mL/min. Patients remaining in AF at the end of the procedure were electrically cardioverted back to sinus rhythm. Remapping of all PVs postcardioversion was performed to confirm PVI. PVI was considered complete when spontaneous associated PV potentials were no longer recorded by the circular mapping catheter (entrance block), and PV to LA dissociation was noted either spontaneously or with PV pacing (exit block). A waiting time of ≥20 minutes after index isolation was used to monitor for early PV reconduction; if spontaneous reconnection occurred, reconnected PVs were reisolated. No induction testing (using burst pacing or isoproterenol infusion), prophylactic linear ablation lesions, or ablation of complex fractionated atrial electrograms were performed.
Adenosine-Guided Ablation
After confirmation of PVI, provocative testing with ≥12 mg of intravenous adenosine was performed to evaluate the presence of dormant conduction in 40 patients from the Montreal Heart Institute (adenosine-guided group, Figure 1 ). Adenosine dosing was titrated to achieve ≥1 blocked P wave or a sinus pause ≥3 seconds. Sites of dormant conduction, as defined by the reappearance of PV activity recorded on an appropriately positioned circular mapping catheter for ≥1 beat, were noted on the electroanatomic map, and supplementary RF energy was delivered at sites of breakthrough until dormant conduction could no longer be elicited. The process was then repeated for each Figure 1 . Adenosine-guided ablation. A, The evaluation of dormant pulmonary vein (PV) conduction. After pulmonary vein isolation, the LSPV is interrogated. On the first beat, only atrial (A) and ventricular (V) far-field signals, but no pulmonary vein potentials (P), are observed on the circular mapping catheter (PV; 20 poles). After the rapid administration of intravenous adenosine, atrioventricular nodal block is induced (last 2 beats) with a coincident recovery of pulmonary vein entrance conduction (P). The pulmonary vein activation sequence demonstrates the earliest pulmonary vein activation as occurring at bipoles 11 to 12 and 13 to 14. The region proximal to this activation was then targeted for further ablation. B, The elimination of dormant PV conduction. After further ablation was performed, the pulmonary vein was reinterrogated. After the rapid administration of intravenous adenosine, AV block is again induced (first 2 beats), although on this occasion there is no further evidence of left atrium-pulmonary vein conduction (no PV potentials are recorded and only atrial far-field signals remain).
PV. The procedure end point was confirmation of bidirectional block in all veins despite repeat provocative adenosine.
Pace-Capture-Guided Ablation
After confirmation of PVI, high-output pacing from the ablation catheter's distal bipole was performed while slowly moving the catheter along the entire circumference of the index ablation line (output 10 V, 2 ms pulse width; reduced in regions susceptible to far-field capture such as near the appendage) in 40 patients from the Florida Hospital Cardiovascular Institute (pace-capture group, Figure 2) . Pacing was performed on or as close to the ablation line as possible with careful attention to avoid parallel orientation of the ablation catheter tip to the tissue, thus helping to prevent inadvertent capture from the proximal electrode of the distal bipole.
The presence or absence of local LA capture on the ablation line was monitored according to the atrial signal of the coronary sinus catheter, as well as PV signals on the circular mapping catheter. Lack of local LA capture was considered to represent a site of efficacious ablation. Conversely, the presence of local LA capture was considered indicative of incomplete ablation and the presence of a residual gap. Additional RF energy was delivered at sites of local LA capture until capture was no longer elicited. The procedure end point was confirmation of loss of pace-capture along the entire circumference of the ablation line.
In a subset of 25 patients, adenosine testing was also undertaken as outlined above, after all sites of pace-capture had been eliminated. In this subset of patients, sites of dormant conduction were noted; however, no further ablation was performed.
Postablation Follow-Up and Outcomes
All patients were discharged home within 2 days after the procedure. Postprocedure, patients continued anticoagulation with dabigatran or warfarin (to maintain an international normalized ratio of 2-3) for a minimum of 2 months. Antiarrhythmic medications (sotalol, propafenone, flecainide, or dofetilide) were continued for a maximum 3 months postablation after which they were discontinued. Patients were followed up in the outpatient clinic of their respective institutions with 12-lead ECG and 24-h Holter at 3, 6, and 12 months postablation. The primary outcome was the time to first recurrence of symptomatic electrocardiographically documented AF or atrial flutter/tachycardia in the absence of antiarrhythmic drug therapy. AF or atrial flutter/tachycardia qualified as an arrhythmia recurrence after ablation if it lasted 30 seconds or longer and was documented by 12-lead ECG, surface ECG rhythm strips, 24-h Holter or transtelephonic monitor recordings. A blanking period of 3 months after the initial ablation was used such that recurrences during this time were not counted. No patients were lost to follow-up, and all patients completed the required outpatient visits and monitoring.
Statistical Analysis
Continuous variables are expressed as the mean±SD (or median, interquartile range) and were compared Student t tests or Wilcoxon rank-sum tests for continuous variables. Categorical variables are expressed as frequency and percentage and were compared by χ 2 or Fisher exact test. All tests were 2 sided. A P<0.05 was considered statistically significant. All analyses were performed using STATA 10.1 (Stata-Corp, College Station, TX). A total of 25 patients per group were required to provide >80% power to detect a 50% difference in the incidence of residual PV conduction unmasked by high-output pacing versus adenosine, assuming an average of 4 PVs per patient and a 2-tailed α of 0.05. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed on the written article.
Results
Baseline Parameters
A total of 80 consecutive patients (59.4±11.9 years; 72.5% male) were enrolled in the study protocol. The mean AF duration before enrollment was 56.1±66.9 months, with patients having failed 1.4±1.0 antiarrhythmic medications before the procedure. Overall, the mean LA diameter was 39.1±6.0 mm, and left ventricular ejection fraction was 61.5±6.6%. Only 8 patients (10%) had a CHADS 2 (Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke) score >1. The baseline characteristics broken down by study group are presented in the Table. Patients in the adenosine-guided ablation group were more likely to be male and had a longer duration of AF. Otherwise the groups were comparable.
Ablation Procedure
The end point of electrical isolation of all PVs (bidirectional entrance and exit block) was achieved in all patients. The mean procedure duration was 201.4±68.2 minutes (venous punctures to groin compression) with mean fluoroscopy duration of 53.2±26.1 minutes and radiofrequency application duration of 60.0±22.7 minutes.
In the adenosine-guided group, dormant conduction was unmasked in 34 of 152 PVs (22.4%) in 21 of 40 patients (52.5%). Of those patients with dormant conduction, an average of 1.38 PVs per patient was affected. PV reconnection was transient in 27 PVs and sustained in 7 PVs. Dormant conduction was documented in 12 right superior pulmonary vein (RSPV), 5 right inferior pulmonary vein (RIPV), 9 left superior pulmonary vein (LSPV), and 8 left inferior pulmonary vein (LIPV).
In the pace-capture-guided group, high-output pacing was performed at an average of 20.0±1.8 sites per venous pair (range, 14-24). Pace-capture was documented in 39 of 156 PVs (25.0%) in 20 of 40 patients (50%). Of those patients with manifest pace-capture, an average of 1.86 PVs per patient was affected. Pace-capture was documented in 12 RSPVs, 5 RIPVs, 16 LSPVs, and 6 LIPVs.
A subset of 25 patients underwent adenosine testing after targeted ablation based on locations of local pace-capture. Of these 25 patients, dormant conduction was unmasked in 6 patients (10 of 86 PVs). The prevalence of dormant conduction after pace-capture-guided ablation was significantly lower than that observed after PVI alone (P=0.041 per PV, and P=0.032 per patient; Figure 3 
Freedom From AF
At a mean follow-up of 329.2±124.8 days, the single procedure (off AAD) freedom from AF was 65.0% in the pace-capture group and 67.5% in the adenosine-guided group (Figure 4 ; log-rank P=0.378). In exploratory multivariate analyses, there was no significant difference in freedom from recurrent AF with pace-capture-guided versus adenosine-guided ablation (hazard ratio, 1.57; 95% confidence interval, 0.58-4.26; P=0.376). There were no complications in the pace-capture group, and 1 tamponade requiring percutaneous drainage in the adenosine-guided group.
Discussion
We have demonstrated the following key findings. In patients with a history of drug-refractory paroxysmal AF undergoing PVI: (1) A similar rate of residual PV conduction was unmasked by high-output pacing compared with adenosine provocation; (2) High-output pacing resulted in a significant reduction in the incidence of dormant conduction revealed by adenosine; (3) Exploratory analyses suggest that a high-output pacing approach results in comparable long-term freedom from recurrent AF when compared with adenosine-guided ablation.
These findings have important clinical implications. Although wide circumferential PVI is an established treatment for patients having AF, a significant minority (≈30%) of patients will require a second intervention attributable to arrhythmia recurrence. Although the persistence of extra pulmonary triggering foci and an AF-maintaining re-entrant substrate have been proposed as potential pathogenetic factors, considerable evidence has demonstrated that the majority of arrhythmia recurrences reflect recovery of electric conduction between PVs and the LA after apparently successful initial isolation (ie, PV-LA reconnection or reconduction). In other words, the failure to achieve lasting PV-LA conduction block at the index ablation procedure (because of [1] intra-atrial variability in tissue depth, and tissue contact/catheter stability, [2] edema formation, and [3] operator competency) has been pathogenetically linked to later arrhythmia recurrences. Unfortunately, the accepted procedural end points of PVI (ie, entrance and exit conduction block) do not always represent the index creation of later contiguous transmural scar. Innovative intraprocedural techniques, such as the use of adenosine and the use of high-output pacing along the ablation line, represent means to acutely differentiate permanent PVI from reversible dormant conduction. [9] [10] [11] [12] 14, 15 It is postulated that delivering additional ablation targeting these regions of residual myocardial viability can improve the durability of the index lesion set, and in turn optimize longer term patient outcomes.
In effect, this is what we have observed. The addition of pace-capture-guided ablation to standard PVI resulted in a significant decrease in the incidence of adenosine provoked dormant conduction with a seemingly comparable longer term success to that of adenosine-guided ablation (ie, the identification and targeted ablation of regions of dormant conduction).
The evaluation of new approaches to ablation requires a comprehensive appraisal of the risks and complexity of the technique, as well as its potential effect on clinical outcome. Although a comparable procedural safety and longer term efficacy were observed with both pace-capture-guided and adenosine-guided ablation, it is important to consider that each technique has its own inherent advantages and disadvantages. Adenosine-guided ablation, which is based on the observation that the acute administration of intravenous adenosine results in restored excitability and PV-LA conduction by hyperpolarizing the reversibly injured antral LA cardiomyocytes, is limited by significant cost (requiring a minimum of 4 separate intravenous challenges), side-effects, contraindications (ie, those with bronchospastic airway disease), as well as potential complications (prolonged asystole and AF induction). [16] [17] [18] Conversely, pace-capture-guided ablation, which is based on the principle that an effective ablation lesion will result in the generation of local nonexcitability, by definition necessitates the presence of an organized atrial rhythm. In addition, the effective use of high-output pacing is dependent on operator experience. For example, loss of capture because of inadequate tissue contact during pacing may be misconstrued as an effective ablation site and thus compromise procedure efficacy. Conversely, atrial far-field capture may be misinterpreted as an area of vulnerable myocardium leading to unnecessary (and potentially harmful) RF delivery. Specifically, careful attention must be paid to ensure the ablation catheter is oriented as perpendicular as possible to prevent inadvertent capture of atrial tissue outside, or adjacent to, the ablation line by the proximal electrode of the distal bipole. Similarly, it is important to limit pacing output in anatomically susceptible locations such as the ridge between the left superior PV and the LA appendage. Moreover, the use of this technique was associated with longer procedure and fluoroscopy durations. Thus, whereas adenosine-guided ablation is feasible (although challenging) in AF, pace-capture-guided ablation offers the advantage that it can be used to identify gaps in not only the PV encircling ablation line, but also other sites of atrial ablation (such as focal or linear ablation sites).
Limitations
This report details an observational comparison between 2 different techniques used to identify regions of myocardial viability. The major limitations of this study are its nonrandomized design and relatively low number of patients in each group. Although the study was specifically designed to compare rates of residual PV conduction, it was adequately powered (>80%) to detect only large differences in clinical recurrences (ie, hazard ratios >2). Because smaller effect sizes cannot be excluded, these secondary analyses were considered exploratory. Moreover, judgment of the effectiveness of AF ablation techniques is dependent on the quality of clinical follow-up. In our case, we attempted to maximize detection of arrhythmia recurrences through the use of serial 24-h Holter monitors. It is possible that the use of longer monitoring durations and loop recorders may have detected more arrhythmia episodes. Finally, the use of further ablation geared toward the elimination of residual or dormant PV conduction remains unknown. In the case of pace-capture-guided ablation, both observational studies were lacking comparator groups. In the case of adenosine-guided ablation, although most of the previous observational studies have been positive not all have been in agreement. [9] [10] [11] 13, 19 It is hoped that the results from the international multicenter randomized trial (the Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination [ADVICE] trial; ClinicalTrials.gov #NCT01058980) will answer the question as to whether elimination of dormant conduction unmasked by intravenous adenosine will result in fewer symptomatic AF recurrences compared with standard PVI.
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Conclusions
A similar incidence of residual PV conduction is unmasked by high-output pacing and adenosine administration. Targeting PV conduction identified by high-output pacing results in a significant reduction in dormant conduction revealed by adenosine. Exploratory analyses suggest that the 2 approaches to unmasking residual PV conduction yield comparable longterm freedom from recurrent AF. The increased cost associated with adenosine must be weighed against the longer procedure and fluoroscopy time associated with pace-capture. The use of these approaches needs to be evaluated in a larger scale prospective randomized trial.
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